March 20, 2018 06:13 AM EDT

Leapfrogging rivals, Roche's Tecentriq plus chemo nabs PFS endpoint in frontline lung cancer segment

John Carroll

Editor & Founder

Roche has nabbed the first shot at a frontline indication for a significant share of the all-important lung cancer market with today’s news that their …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Leapfrogging rivals, Roche's Tecentriq plus chemo nabs PFS endpoint in frontline lung cancer segment

John Carroll

Editor & Founder

Sign up to read this article for free.

CagriSema’s weight loss data disappointed. What does Novo do next?

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

CMS explains what went into its first round of drug price negotiations

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Deerfield wins fight to acquire Singular Genomics, beating out Tang Capital’s Concentra

Leapfrog­ging ri­vals, Roche's Tecen­triq plus chemo nabs PFS end­point in front­line lung can­cer seg­ment

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Leapfrogging rivals, Roche's Tecentriq plus chemo nabs PFS endpoint in frontline lung cancer segment

CagriSema’s weight loss data disappointed. What does Novo do next?

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

CMS explains what went into its first round of drug price negotiations

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Deerfield wins fight to acquire Singular Genomics, beating out Tang Capital’s Concentra